FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
Status:
Recruiting
Trial end date:
2044-06-30
Target enrollment:
Participant gender:
Summary
This is a phase 1 study of FT522 administered with rituximab in participants with
relapsed/refractory B-cell lymphoma (R/R BCL). The primary objectives of the study are to
evaluate the safety and tolerability of FT522 in combination with rituximab, and to determine
the recommended phase 2 dose (RP2D) of FT522 in combination with rituximab; each objective
will be assessed with or without conditioning chemotherapy.